LD-2 disclosure · 3rd Quarter - Report
FIGHT TO LIVE
Coverage · No income or expenses were reported on this filing.
Client
- Name
- FIGHT TO LIVE
- Description
- Community for change at the FDA to transform Cancer and Terminal Diseases
- Location
- California · United States of America
Registrant
- Description
- Law firm/Lobbying Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
1 issueHealth Issues
The Patient Choice Act - HR 2090 To obtain provisional approval of drugs in clinical trials for patients with terminal and life threatening illnesses. This legislation would allow individuals to obtain drugs outside of the scope of Phase I and Phase II clinical trials.
LobbyistsJONATHAN ERIC AGIN